The inaugural Peptide Based Therapeutics Summit unites the pioneers within peptide based drugs across diverse diseases and therapeutic approaches.

Since 2006, BIO KOREA has hosted its International Convention annually to promote the growth and revitalization of the global bio-health industry. Participants will have the opportunity to explore the latest trends, technologies, and global business expansion opportunities alongside leading international academics, professionals, and CEOs.

Each year, the TIDES conference scientific agenda includes 150+ of the industry’s top scientists to present the latest science and industry updates across the entire spectrum.

CPHI Americas 2026 moves beyond the traditional trade show format to create a premium, content-first experience specifically centered around the contract development and manufacturing ecosystem.

The IOPC is the leading event at the forefront of innovation, research, and novel developments in oligonucleotides and peptides.

The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with 20,000 industry leaders from across the globe.

CPHI Korea is a dynamic meeting place where pharmaceutical suppliers, purchasers and decision makers get together for three days of uninterrupted business. Exhibiting companies showcase products from across the entire pharma supply chain.

RNA Leaders is the #1 must-attend event focused on RNA medicines such as RNAi, antisense, non-linear RNAs, RNA editing and targeting RNA, as well as manufacturing development of mRNA therapies and vaccines.

Launched in 1986, BioJapan is Asia's premier bio-industry partnering event. As the world’s longest-running biotech exhibition, BioJapan continues to drive innovation and collaboration in the industry through its comprehensive event ecosystem, seminars, and partnering programs.

Sheri Ambriz, MBA took the stage at TIDES USA 2025 in San Diego, CA, to share insights on green approaches to peptide and peptide–oligonucleotide conjugate manufacturing.

Watch Tim Nieters, MBA present a case study at TIDES USA 2024, showcasing process development & GMP manufacturing of DOTAGA-labeled peptide & POC-based products.

This presentation will review new USP recommendations in the context of existing regulatory guidance, with particular focus on peptide-related impurities, their identification...

This presentation will focus on the development of the latest GLP-1 mimetics and GLP-1/GIP dual agonists, with unparalleled efficacy and ease of delivery.

Peptide receptor radionuclide therapy (PRRT) is a targeted therapeutic strategy that uses peptides to deliver cytotoxic radiation levels to specific receptors overexpressed in cancer cells. This case study presents a manufacturing process for DOTAGA-Labeled urea-based peptide PSMA inhibitor API, DOTAGA-(I-y)fk(Sub-KuE).